Navigation Links
Vical Names Andrew de Guttadauro Vice President, Corporate Development

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the enhancement of its management team with the appointment of Andrew R. de Guttadauro as Vice President, Corporate Development.

Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company's Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceuticals, where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the United States Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.

Vijay B. Samant, Vical's President and Chief Executive Officer, said, "We are very pleased to welcome Andrew to Vical's management team at this exciting time in the company's development. His proven leadership capabilities, solid project management skills, and breadth of experience in product sales and marketing, add another dimension to our current capabilities. As we advance with our independent product development programs, we look forward to applying Andrew's expertise in product commercialization, which includes hands-on contributions to the successful launch and market expansion of multiple products."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Susan Neath

Vical Incorporated Porter Novelli Life Sciences

(858) 646-1127 (619) 849-6007


SOURCE Vical Incorporated

Copyright©2007 PR Newswire.

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
(Date:11/23/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a leading ... vascular surgery, announced today that it will participate in the ... Wednesday, December 2, 2015 at The New York Palace Hotel ... Pat Mackin , President and Chief Executive Officer. ... --> A live webcast of the Company,s ...
(Date:11/23/2015)... 23, 2015  Oxis Biotech, Inc. (OXIS), a ... OXIS] and [Euronext Paris: OXI.PA] announced today its ... Center received notification from the U.S. Food and ... their planned combination Phase 1/Phase 2 clinical trial ... develop and commercialize OXS-1550, a novel therapy for ...
(Date:11/23/2015)... Research and Markets ( ) has announced the addition ... Application and Geography - Global forecast to 2020" report ... --> The overall service laboratory market is expected to ... Billion by 2020, at a CAGR of 6.5% from 2014 ... The market in APAC is expected to witness the ...
(Date:11/23/2015)... DUBLIN, Ireland , November 23, 2015 ... announced the addition of the  "2016 Global ... Suppliers and Emerging Market Entrants"  report to ... has announced the addition of the  "2016 ... Major Suppliers and Emerging Market Entrants"  report ...
Breaking Biology Technology:
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):